Calculating Your Risk: Scoring Tools and Factors

When you are diagnosed with DCIS, one of the most difficult questions to answer is: “How likely is this to come back?” To help answer this, doctors use risk stratification tools. These are models that combine different pieces of your medical data—like your age, the size of the lesion, and how the cells look—to estimate your risk of a future breast event ^[1][2].

It is important to understand that these tools provide a statistical “best guess” based on thousands of other patients; they cannot predict with 100% certainty what will happen to you individually.

The USC/Van Nuys Prognostic Index (VNPI)

The USC/Van Nuys Prognostic Index (VNPI) is one of the oldest tools for DCIS. The commonly used modified version assigns a score from 4 to 12 based on four key factors:

1. Age: Younger patients generally receive a higher score because they have a higher risk of recurrence over their lifetime ^[1].
2. Size: Larger areas of DCIS increase the score ^[3].
3. Margins: The width of the “safety zone” of healthy tissue removed during surgery ^[1].
4. Pathologic Category: This combines the Nuclear Grade (how abnormal the cells look) and the presence of Comedo Necrosis (dead cell plugs) ^[1].

Based on these inputs, patients are grouped into Low Risk (4–6), Intermediate Risk (7–9), or High Risk (10–12) ^[1]. Historically, surgeons used these scores to help decide between a lumpectomy alone, adding radiation, or performing a mastectomy ^[1].

Limitations of the VNPI: While helpful, the VNPI has limited external validation and is not a universally accepted stand-alone rule for choosing treatment. Studies have shown that different pathologists may score the same sample differently, which can change your score ^[4]. Additionally, some “low-risk” patients in VNPI studies still had a recurrence rate of over 20% after ten years. Today, many clinicians use it only as one discussion aid rather than a strict calculator ^[5][6].

The Oncotype DX DCIS Score

The Oncotype DX DCIS Score is a more modern approach that uses genomics. It looks at the activity of 12 specific genes within your DCIS cells to estimate the 10-year risk of the cancer returning in the same breast, either as DCIS or as invasive cancer, if treated with breast-conserving surgery alone ^[2][7].

The test provides a score from 0 to 100:

• Low Score (<39): Lower risk of recurrence.
• Intermediate Score (39–54): Moderate risk.
• High Score (≥55): Higher risk ^[2].

Utility and Limitations: This test estimates recurrence risk after breast-conserving surgery alone. While it is sometimes used to help women over 50 decide if they want to skip radiation after a lumpectomy, it has not been shown to predict who will safely benefit from radiation. In some studies, the score changed the treatment recommendation in about 26% to 35% of cases ^[8]. However, a low score is not a guarantee that radiation can safely be omitted, and decision-impact studies showing a changed recommendation do not prove better outcomes. The score estimates the risk of recurrence; it does not prove that radiation will or will not work for you specifically ^[9]. Experts also note that it is an expensive test, and its cost-effectiveness is still debated in the medical community ^[10].

Clinical Factors That Influence Risk

Beyond these formal scores, several clinical factors play a major role in your overall risk profile:

• Age at Diagnosis: Patients diagnosed under the age of 40 or 45 tend to have a higher risk of recurrence, especially for invasive cancer, compared to older patients ^[11][3].
• Race and Ethnicity: Studies have observed that Black/African American women may face a higher risk of the cancer returning as invasive disease ^[11]. This is not biological destiny, but a complex area of research influenced by tumor biology, access to care, and treatment quality differences.
• Method of Detection: DCIS that is found because you or your doctor felt a lump (palpable) is generally considered higher risk than DCIS caught only on a screening mammogram ^[11].
• Margins: While you cannot control margin width—it is primarily determined by the lesion’s spread, the surgery, and pathology—achieving a negative margin through treatment is a highly modifiable risk factor. Having “ink on the tumor” (a positive margin) significantly increases the risk of the cancer coming back ^[3][12].

By combining these clinical factors with formal scoring tools, you and your care team can move away from a “one-size-fits-all” approach and toward a treatment plan that fits your specific level of risk.